References
- Clark RV, Hermann DJ, Cunningham GR, et al. Marked suppression of dihydrotestosterone in men with benign prostatic hyperplasia by dutasteride, a dual 5α-reductase inhibitor. J Clin Endocrinol Metab 2004;89:2179–84
- Hong SK, Min GE, Ha SB, et al. Effect of the dual 5alphareductase inhibitor, dutasteride, on serum testosterone and body mass index in men with benign prostatic hyperplasia. BJU Int 2010;105:970–4
- Harman SM, Metter EJ, Tobin JD, et al. Baltimore Longitudinal Study of Aging: longitudinal effects of aging on serum total and free testosterone levels in health men. J Clin Endocrinol Metab 2001;86:724–31
- Comhaire FH. Andropause hormone replacement therapy in the ageing male. Eur Urol 2000;38:655–62
- Haentjens P, Magazziner J, Colon-Emeric CS, et al. Meta-analysis: excess mortality after hip fracture among older women and men. Ann Intern Med 2010;152:380–90
- Nguyen ND, Center JR, Eisman JA, et al. Bone loss, weight loss, and weight fluctuation predict mortality risk in elderly men and women. J Bone Miner Res 2007;22:1147–54
- Yoshimura N, Muraki S, Oka H, et al. Prevalence of knee osteoarthritis, lumbar spondylosis and osteoporosis in Japanese men and women: the research on osteoarthritis/osteoporosis against disability study. J Bone Miner Metab 2009;27:620–8
- Orimo H, Hashimoto T, Yoshimura N, et al. Nation-wide incidence survey of femoral neck fracture in Japan, 1992. J Bone Miner Metab 1996;15:100–6
- Homma Y, Gotoh M, Yokoyama O, et al. Outline of JUA clinical guidelines for benign prostatic hyperplasia. Int J Urol 2011;18:741–56
- Orimo H, Nakamura T, Hosoi T, et al. Japanese 2011 guidelines for prevention and treatment of osteoporosis--executive summary. Arch Osteoporos 2012;7:3–20
- Matsumoto AM, Tenover L, McClung M, et al. The long-term effect of specific type 2 5α-reductase inhibition with finasteride on bone mineral density in men: results of 4-year placebo controlled trial. J Urol 2002;167:2105–8
- Jacobsen SJ, Cheetham TC, Haque R, et al. Association between 5α reductase inhibition and risk of hip fracture. JAMA 2008;300:1660–4
- Amory JK, Anawalt BD, Matsumoto AM, et al. The effect of 5α-reductase inhibition with dutasteride and finasteride on bone mineral density, serum lipoproteins, hemoglobin, prostate specific antigen and sexual function in health young men. J Urol 2008;179:2333–8
- Shigehara K, Koh E, Sakamoto J, et al. Effect of dutasteride on lower urinary tract symptoms and general health in men with benign prostatic hyperplasia and hypogonadism: a prospective study. Aging Male 2014;17:51–6
- Martin AC. Osteoporosis in men: a review of endogenous sex hormones and testosterone replacement therapy. J Pharm Pract 2011;24:307–15
- Szulc P, Munoz F, Claustrat B, et al. Bioavailable estradiol may be an important determinant of osteoporosis in men: the MINOS study. J Clin Endocrinol Metab 2001;86:192–9
- Khosla S, Melton LJ, Atkinson EJ, et al. Relationship of serum sex steroid levels to longitudinal changes in bone density in young versus elderly men. J Clin Endocrinol Metab 2001;86:3555–61
- Tracz MJ, Sideras K, Bolona ER, et al. Clinical review: testosterone use in men and its effects on bone health. A systematic review and meta-analysis of randomized placebo-controlled trials. J Clin Endocrinol Metab 2006;91:2011–16